IAVI

IAVI and Moderna partner to tackle broad global health priorities using mRNA for vaccines and antibodies

NEW YORK, NY and CAMBRIDGE, MA / April 7, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the nonprofit scientific research organization IAVI today announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats. These diseases - HIV/AIDS, tuberculosis (TB), antimicrobial-resistant enteric infections, and COVID-19 - are estimated to have caused at least 95 million new infections and more than 4 million deaths in 2020 alone. The collaboration combines the power of Moderna's mRNA platform and IAVI's expertise in discovery and product development to advance vaccines and antibodies designed to be globally accessible, especially in low-income countries where the targeted diseases have high incidence and prevalence.

Read More →

Webinar: Ending TB: Right dose, right time

On 11 April 2022, FIND, the global alliance for diagnostics, TB Alliance and the International AIDS Vaccine Initiative (IAVI) will host a webinar bringing together a panel of experts to review both new and experimental tools that have the potential to end TB for good, and what is needed to bring them to scale and achieve public health impact.

Read More →

TB vaccine advocacy social media fellowship

The International AIDS Vaccine Initiative (IAVI) announced a social media fellowship starting the last week of January 2022.

Read More →

Spanish pharmaceutical company Zendal and IAVI partner to advance the TB vaccine candidate MTBVAC into efficacy trials

-- TB kills 1.4 million people a year, an infectious disease toll only recently surpassed by COVID-19.
-- COVID-19 has reversed years of progress in TB response, costing additional lives and adding to the urgency of the global TB problem.
-- MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.

Read More →

Updated TB Vaccine Development Pathway

The Tuberculosis Vaccine Initiative (TBVI) and the International AIDS Vaccine Initiative (IAVI) have updated the TB Vaccine Development Pathway.

Read More →

GSK candidate vaccine demonstrates sustained level of protection against active pulmonary TB

-- Final analysis of phase IIb study published today in the New England Journal of Medicine and presented at the 50th Union World Conference on Lung Health.

-- Final results confirm the innovative TB candidate vaccine’s efficacy level and acceptable safety profile in three-year clinical trial conducted in sub-Saharan African regions.

Read More →

Page 1 of 1 · Total posts: 6

1